12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HMPL-004: Phase III started

Nutrition Science Partners began the 2-part, international Phase III NATRUL-4 trial to evaluate 600 mg oral HMPL-004 thrice daily for an 8-week, open-label phase followed by a double-blind, placebo-controlled, 52-week maintenance phase in 460 subjects with active mild to moderate ulcerative colitis (UC) who have an inadequate response to mesalamine. The maintenance phase will enroll...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >